Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
uncontrolled hypertension and advanced chronic kidney disease (CKD). Consequently, the company said that it will recognize an impairment loss of around DKK 5.7 billion related to the intangible assets in the second quarter of 2024. Such recognition is expected to negatively impact operating profit growth by around 6 percentage points at the constant exchange rate (CER) in 2024. This adjustment revises the previously stated operating profit outlook of 22% to 30% growth at CER, as communicated in their financial report for the first quarter of 2024. Novo Nordisk is slated to announce its financial results for the first six months of 2024 and update its financial outlook for 2024 on Aug 7, 2024. Based on interim analysis, an independent data monitoring determined that the study did not meet its primary endpoint of reducing systolic blood pressure from baseline. This conclusion triggered Novo Nordisk's decision to halt the CLARION-CKD study. Year to date, shares of NVO have jumped
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Fixing the Broken Rung: Better approaches to promotion and talent development [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN [Yahoo! Finance]Yahoo! Finance
- Keep faith in China, Li Qiang tells business at ‘Summer Davos' [Yahoo! Finance]Yahoo! Finance
- SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women [Yahoo! Finance]Yahoo! Finance
- Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 11-K
- NVO's page on the SEC website